Significant Ownership of EVENTIDE ASSET MANAGEMENT, LLC
- Signature - Title
- /s/ Peter J. Luiso - Peter J. Luiso, General Counsel
- Location
- Boston, MA
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by EVENTIDE ASSET MANAGEMENT, LLC.
Follow Filing Activity
Follow EVENTIDE ASSET MANAGEMENT, LLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of EVENTIDE ASSET MANAGEMENT, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| BBNX | Beta Bionics, Inc. | Common Stock | 11% | $52,456,043 | 4,857,041 | Eventide Asset Management, LLC | 31 Jan 2025 | ||
| XMTR | Xometry, Inc. | Class A Common Stock, par value $0.000001 per share | 6.7% | $78,356,159 | 3,151,897 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| COLL | Collegium Pharmaceuticals, Inc. | Common Stock, par value $0.001 per share | 5.9% | $85,425,162 | 1,876,239 | Eventide Asset Management, LLC | 31 Dec 2025 | ||
| Inventiva S.A. | Ordinary Shares, nominal value Euro 0.01 per share | 4.6% | 9,368,517 | -7.4% | Eventide Asset Management, LLC | 31 Dec 2025 | |||
| MIRM | Mirum Pharmaceuticals, Inc. | Common Stock, par value $0.0001 per share | 4.1% | $165,372,042 | -$40,549,990 | 2,093,582 | -20% | Eventide Asset Management, LLC | 31 Dec 2025 |
| LXEO | Lexeo Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 3.7% | $4,544,189 | 1,234,834 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| NKTR | Nektar Therapeutics | Common Stock, $0.0001 par value | 3.6% | $4,921,000 | 6,650,000 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| INZY | Inozyme Pharma, Inc. | Common Stock, par value $0.0001 per share | 3.5% | $2,353,200 | 2,220,000 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| CLDX | Celldex Therapeutics, Inc. | Common Stock, par value $0.001 | 2% | $30,459,938 | 1,356,186 | Eventide Asset Management, LLC | 30 Jun 2025 | ||
| EVH | Evolent Health, Inc. | Class A Common Stock, par value $0.01 per share | 0% | $7,109 | -$26,106,812 | 1,713 | -100% | Eventide Asset Management, LLC | 31 Dec 2025 |
| AURA | Aura Biosciences, Inc. | Common Stock, par value $0.00001 per share | 0% | $0 | -$22,524,940 | 0 | -100% | Eventide Asset Management, LLC | 31 Mar 2025 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Common Stock, $0.001 par value per share | 0% | $0 | -$6,399,327 | 0 | -100% | Eventide Asset Management, LLC | 31 Mar 2025 |
| VYNE | VYNE Therapeutics Inc. | Common Stock, par value $0.0001 | 0% | $0 | -$619,615 | 0 | -100% | Eventide Asset Management, LLC | 30 Sep 2025 |
Schedules 13D/G Reported by EVENTIDE ASSET MANAGEMENT, LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.